In Situ Hybridization Market

The global in situ hybridization market is projected to reach USD 2.8 billion by 2027 from USD 1.5 billion in 2022, at a CAGR of 12.6% during the forecast period. One of the key driving factors of the in situ hybridization market is the increasing awareness of companion diagnostics and the growing incidence of cancer and genetic disorders. Moreover, the growth of the ISH market is largely driven by a rise in government and private funding in life sciences and cancer research, the increasing number of reagent rental agreements, and the application of innovative technologies and methodologies in the fields of tissue and in vitro diagnostics.

The market for in situ hybridization is competitive and highly consolidated, with key players strategizing to capture the market. Prominent players in the ISH market are Abbott (US), Thermo Fisher Scientific (US), Danaher Corporation (US), Merck KGaA (US), F. Hoffmann-La Roche AG (US), BioView (Israel), Agilent Technologies (US), Biocare Medical (US), Bio-Techne Corporation (US), QIAGEN N.V. (Germany), PerkinElmer (US), Enzo Biochem (US), Bio-Rad Laboratories (US), Abnova Corporation (Taiwan), BioGenex Laboratories (US), OpGen US), Bio SB (US), GeneMed Biotechnologies (US), Abcam plc. (UK), Creative Bioarray (US), BioCat GmbH (Spain), ZytoVision (Germany), NeoGenomics Laboratories (US), and Oxford Gene Technology (UK).

To know about the assumptions considered for the study download the pdf brochure

Abbott (US)

Abbott (US) caters to the in situ hybridization market via its diagnosis business segment. Molecular division products such as kits and reagents, accessories, instruments, and software are a part of the company’s product portfolio. Abbott is recognized for its robust presence across different geographies including, the US, Germany, India, South Korea, and North America. The company’s key focus lies in product development and commercialization of in situ hybridization to sustain market competition.

F. Hoffmann-La Roche AG

F. Hoffmann-La Roche AG has a strong market presence in North America, and Europe region. The company offers in situ hybridization products for the diagnosis of patients suffering from cancer. F. Hoffmann-La Roche AG has adopted organic growth strategies and has a prime focus on the development and commercialization of in situ hybridization candidates in the pipeline. Therapeutic applications such as neurological disorders and pulmonary ailments are two of the key areas of investment for the company through which it is expected to broaden its hold on the in situ hybridization market. The revenue in the company’s Life Sciences segment increased by 8% in the last year due to the increasing demand in developed and emerging markets for life science products.

Related Reports:

In Situ Hybridization Market by Products (Consumables, Instruments, Software), Technology (DNA FISH, RNA FISH, PNA FISH, CISH), Application (Cancer, Immunology, Neuroscience, Cytology), End User (Hospitals, Pharma, Biotech, CROs) – Global Forecast to 2027

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]